What type of study is this?

This is a Pre-Registered Trial study.

What question did this study set out to answer?

To evaluate 12-month treatment persistence and effectiveness of guselkumab versus IL-17 inhibitors in psoriatic arthritis.

April 30, 2026Lara D. Veeken

E152 Guselkumab and IL-17 inhibitors show comparable treatment persistence and effectiveness in psoriatic arthritis: 12-month results of the PsABIOnd observational study

View Full Paper

Ask AI

Bookmark

Authors

SSStefan SiebertUniversity of Glasgow MSMohamed SharafJohnson & Johnson (United States)FBF BehrensGoethe University Frankfurt

Discussion

Member takes

Implication

Observational study reveals similar treatment persistence and effectiveness of guselkumab and IL-17 inhibitors in psoriatic arthritis, suggesting real-world benefits.

Key Points

To evaluate 12-month treatment persistence and effectiveness of guselkumab versus IL-17 inhibitors in psoriatic arthritis.
PsABIOnd is a global observational study of adults with psoriatic arthritis starting biologic therapy.
Participants included those receiving initial treatment of guselkumab or IL-17 inhibitors.
Treatment persistence and effectiveness were assessed via Kaplan-Meier estimation and propensity score analysis.
79.6% of guselkumab and 82.7% of IL-17 inhibitor recipients maintained their treatment at 12 months.
Treatment effectiveness across joint, skin, and overall psoriatic arthritis activity was similar.
Findings support real-world efficacy of guselkumab and IL-17 inhibitors.

Cite This Study

Siebert et al. (2026) studied this question.

synapsesocial.com/papers/69f2a4f18c0f03fd6776424d https://doi.org/10.1093/rheumatology/keag121.373

View Full Paper

Ask AI

Bookmark

Implication

Observational study reveals similar treatment persistence and effectiveness of guselkumab and IL-17 inhibitors in psoriatic arthritis, suggesting real-world benefits.

E152 Guselkumab and IL-17 inhibitors show comparable treatment persistence and effectiveness in psoriatic arthritis: 12-month results of the PsABIOnd observational study

Discussion

Member takes

Implication

Key Points

Cite This Study

E152 Guselkumab and IL-17 inhibitors show comparable treatment persistence and effectiveness in psoriatic arthritis: 12-month results of the PsABIOnd observational study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider